Guizhou Sinorda Pharmaceutical Co., Ltd.

Guizhou Sinorda Pharmaceutical Co., Ltd.

导航

Home
About
Product
- Product Center
- R&D pipeline
Platform
Blog
Talent
Contact
- Contact Information
- Online message

language

News Center

Home page

The 2025 Nobel Prize in Physiology or Medicine Announced

Category:

Source:CCTV News

Author:

Release time:2025-10-06 13:56

On October 6, local time, Sweden's Karolinska Institute announced that the 2025 Nobel Prize in Physiology or Medicine will be awarded to scientists Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, in recognition of their groundbreaking research on peripheral immune tolerance.

On October 6, local time, Sweden's Karolinska Institute announced that the 2025 Nobel Prize in Physiology or Medicine will be awarded to scientists Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, in recognition of their groundbreaking research on peripheral immune tolerance.

(CCTV Reporter Hao Xiaoli)

Previous

Next

This pioneer in immunotherapy has achieved several "firsts" in the history of human cancer treatment.

Related content

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

2026-01-29 08:54

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

The 2025 Nobel Prize in Physiology or Medicine Announced

Sinorda Pharmaceutical Named to the "2025 China's Top 101 Innovative Pharmaceutical Companies" List

Guizhou Sinorda Pharmaceutical Co., Ltd.

Email: info1@sinorda.com

Zip code: 550018

Address: Guizhou Province Guiyang City National High-tech Zone West R & D Base

Consultation Hotline

QR code

Business license

Label | Website construction: www.300.cn-GuiYang